Annual Information Update

RNS Number : 2262E

Oxford Biomedica PLC

04 April 2011

 



Oxford BioMedica plc ("Oxford BioMedica" or the "Company")

Annual Information Update for the Twelve Months to 1 April 2011

Oxford BioMedica is providing an annual information update pursuant to Prospectus Rule 5.2 made by the Financial Services Authority.

1.                   Announcements made via a Regulatory Information Service

Date	Announcement
21 April 2010	Board Change - resignation of Nick Woolf
27 April 2010	AGM result
4 May 2010	Total voting rights update
5 May 2010	Holding(s) in Company
13 May 2010	Corporate presentation at Rodman & Renshaw conference
19 May 2010	Interim management statement
27 May 2010	Blocklisting interim review
14 June 2010	ProSavin® clinical trial update
15 June 2010	Directors' interests in shares - Long Term Incentive Plan award
17 June 2010	Holding(s) in Company
18 June 2010	Amendment to 5T4 licence with Cancer Research Technology  and issue of shares
24 June 2010	Collaboration to evaluate TroVax® in mesothelioma
24 June 2010	Notice of interim results
30 June 2010	Total voting rights update
1 July 2010	Notice of R&D presentation for investors and analysts
1 July 2010	Award of grant by Motor Neurone Disease Association
26 July 2010	FDA approval for TroVax® Phase II study in prostate cancer
18 August 2010	Licence agreement with Emergent BioSolutions Inc.
18 August 2010	Holding(s) in Company
24 August 2010	Interim results
15 September 2010	Holding(s) in Company
22 September 2010	TroVax® selected by Windhover and Campbell Alliance as one of the "Top 10 Most interesting Oncology Projects to Watch".
14 October 2010	TroVax® Phase III data published in  journal Clinical Cancer Research
14 October 2010	Change of Advisor and Broker
29 October 2010	Interim management statement
9 November 2010	US IND approval for RetinoStat®
26 November 2010	Blocklisting interim review
13 December 2010	Proposed Firm Placing and Placing and Open Offer of up to £20 million
13 December 2010	Confirmation of underwritten £20 million share issue
14 December 2010	Issue of prospectus
22 December 2010	ProSavin® clinical trial update
23 December 2010	Corporate presentation at JP Morgan Healthcare conference
7 January 2011	Result of Open Offer
7 January 2011	Result of General Meeting
10 January 2011	Directors' interests in shares
12 January 2011	Holding(s) in Company
20 January 2011	Notice of results
31 January 2011	Acquisition of manufacturing facility
31 January 2011	Holding(s) in Company
31 January 2011	Total voting rights update
9 February 2011	Appointment of Head of Manufacturing
2 March 2011	Preliminary results for 2010
15 March 2011	TroVax® Phase III data published in  journal  Cancer Immunology, Immunotherapy
21 March 2011	US IND approval for StarGen™
21 March 2011	Board Change - resignation of Dr Alan Kingsman
22 March 2011	Director's interest in shares
31 March 2011	Annual Report and Accounts and AGM notification
1 April 2011	Annual information update

Details of all regulatory announcements for Oxford BioMedica can be found on the London Stock Exchange website at www.londonstockexchange.com  and on the Oxford BioMedica website at http://www.oxfordbiomedica.co.uk 

2.                  Documents filed with Companies House

Date	Document Type	Description
6 April 2010	SH01 Return of Allotments of Shares	Allotment 1,873,206 1p Ord.
27 April 2010	AGM Special Business	AGM minutes
28 June 2010	SH01 Return of Allotments of Shares	Allotment 1,816,523 1p Ord.
30 September 2010	AR01 Annual Return	Annual return
10 January 2011	SH01 Return of Allotments of Shares	Allotment 400,000,000 1p Ord.

Copies of documents filed at Companies House can be obtained from Companies House, Crown Way, Cardiff CF14 3UZ or through Companies House Direct at www.direct.companieshouse.gov.uk 

3.                  Documents published or sent to shareholders or filed with the UKLA National Storage Mechanism

Date	Description
24 August 2010	Interim Report for 6 months to 30 June 2010
13 December 2010	Prospectus
7 January 2011	General Meeting Resolutions
30 March 2011	Annual report for the year ended 31 December 2010 and Notice of AGM

Copies of all the above documents may be obtained from the Company Secretary at the Company's Registered Office:

This annual information update is filed pursuant to Prospectus Rule 5.2 made by the Financial Services Authority and not for any other purpose and by filing this annual information update neither the Company, nor any other person, takes any responsibility for, or makes any representation, express or implied, as to the accuracy or completeness of, the information contained or referred to below herein. The information referred to below is not necessarily up to date as at the date of this annual information update and the Company does not undertake any obligation to update any such information in the future. Furthermore, such information may have been prepared in accordance with the laws or regulations of a particular jurisdiction and may not comply with or meet the relevant standards of disclosure in any other jurisdiction. Neither this annual information update, nor the information referred to below constitutes, by virtue of this communication, an offer of any securities addressed to any person and should not be relied on by any person.

Oxford BioMedica plc

Medawar Centre

Robert Robinson Avenue

The Oxford Science Park

Oxford

OX4 4GA

04 April 2011

 

END

 

 

AIUKZLBBFZFLBBQ